Sol-Gel Technologies (NASDAQ:SLGL) Issues Earnings Results, Misses Estimates By $0.04 EPS

Sol-Gel Technologies (NASDAQ:SLGL) issued its earnings results on Thursday. The company reported ($2.13) earnings per share for the quarter, missing the consensus estimate of ($2.09) by ($0.04), Zacks reports. The firm had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.30 million. Sol-Gel Technologies had a negative return on equity of 11.80% and a negative net margin of 14.25%.

Sol-Gel Technologies Price Performance

Shares of NASDAQ:SLGL traded down $0.95 during midday trading on Thursday, reaching $35.09. The company’s stock had a trading volume of 19,305 shares, compared to its average volume of 22,531. The company has a market capitalization of $97.76 million, a P/E ratio of -28.53 and a beta of 1.35. Sol-Gel Technologies has a fifty-two week low of $4.02 and a fifty-two week high of $52.26. The business’s fifty day simple moving average is $33.95 and its 200-day simple moving average is $19.45.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Wall Street Zen downgraded Sol-Gel Technologies from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Weiss Ratings restated a “hold (c-)” rating on shares of Sol-Gel Technologies in a report on Wednesday, October 8th. HC Wainwright lifted their price objective on Sol-Gel Technologies from $6.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, October 27th. Finally, Zacks Research raised Sol-Gel Technologies to a “hold” rating in a research report on Tuesday, October 28th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $50.00.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.